Latest News and Press Releases

Company reviews goals and significance of the clinical trial and outlines development and partnering strategy

ROCHESTER, N.Y., July 17, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating Alzheimer’s disease (AD) and...

Patient visits complete in Alzheimer's Disease clinical trial. Company plans to lock database in June and to present topline data in July.

Last patient last visit in SIGNAL-AD Phase 2a study of pepinemab treatment for Alzheimer’s Disease in early June 2024. $8.2 million of new financing in Q1.

ROCHESTER, N.Y., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to...

EXTON, PA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Huntington’s disease (HD) could be called the perfect storm of neurodegenerative diseases. It causes a loss of critical striatal neurons which affect not...

Phase 1/2a Randomized SIGNAL-AD Study of Pepinemab in Alzheimer’s Disease Achieves Full Accrual Expect to Complete 12-months treatment in June, 2024 Company raised over $10 million of new...

ROCHESTER, N.Y., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease...

Significant YTD Progress in Neurology and Oncology Programs New financing of $5MM closed without warrants, derivatives or other financial considerations ROCHESTER, N.Y., May 15, 2023 (GLOBE...

Topline data anticipated in mid-2024 SIGNAL-AD builds on promising data from the Phase 2 SIGNAL Study in Huntington’s Disease ROCHESTER, N.Y., April 25, 2023 (GLOBE NEWSWIRE) -- Vaccinex, Inc....